Healthcare's collision with lower-cost genetic sequencing, mobile tech, AI, and consumerization will transform the trajectory of how we live for the next 10 years.
In the wake of MD Anderson's costly failure with IBM's Watson supercomputer, a Watson backlash brewing in biopharma may lead to a moment of reckoning in life sciences.
Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
This month we will debut a restyled MM&M logo on our website, in a mobile-friendly, redesigned email newsletter, and on the cover of our magazine.
My hope is that all of us do a better job of focusing on value.
Each of this year's Influencers wields significant influence at a major health-related organization and boasts high-profile accomplishments, oftentimes ahead of the aforementioned pain-of- change curve.
Some innovations are still emerging, while others seem more elusive than ever. You'll find many moments whose impact resonates through time.
When the Career and Salary Survey made its debut, in 1987, Eli Lilly's Prozac led the list of mass-market drug launches and AIDS therapy had taken a big step forward with the approval of GlaxoSmithKline's AZT, a year earlier.
Were we trying to celebrate these women for having made hard-won progress in gender parity while also perpetuating a stereotype about them?
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Tuesday, April 25, 2017
- Drugmakers battle for slice of Humira's billions
- Five things for pharma marketers to know: Wednesday, April 26, 2017
- Five things for pharma marketers to know: Thursday, April 27, 2017
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.